Report Overview

The EU Anti-fungal market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 3.23% during the forecast period

Anti-fungals are a class of medications that destroy or inhibit the growth of fungal organisms and are, accordingly, used to treat fungal infections (mycoses) such as candidiasis cryptococcal disease, aspergillosis, and dermatophilosis



Market Drivers

The emerging pipeline of new and developing anti-fungal drugs is likely to present this market with amazing growth opportunities. The development of public-private partnerships in the pharmaceutical industry and the rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for the growing antifungal drug market size. Also, the rising population with a weak immune system, in whom fungal infections are much more than average, will drive the market. The high prevalence of conventional drugs used for the treatment of fungal infections is significantly restraining market growth